Minerva Neurosciences officer files initial insider report

Minerva Neurosciences, Inc. filed an initial insider ownership report for James Joseph O'Connor, who serves as Chief Business Officer and General Counsel.

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. filed an initial insider ownership report for James Joseph O'Connor, who serves as Chief Business Officer and General Counsel. The filing lists him as an officer but not as a director or ten percent owner, and shows no reportable transactions.

Key Terms

Chief Business Officer and GC, ten percent owner, officer

3 terms

Chief Business Officer and GC financial

"officer_title": "Chief Business Officer and GC""

ten percent owner financial

""is_ten_percent_owner": 0"

officer financial

""is_officer": 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in Minerva Neurosciences (NERV) latest Form 3?

The reporting person is James Joseph O'Connor, identified as an officer of Minerva Neurosciences. His title in the filing is Chief Business Officer and General Counsel, and he is not listed as a director or ten percent owner.

What role does James Joseph O'Connor hold at Minerva Neurosciences (NERV)?

James Joseph O'Connor is listed as Chief Business Officer and General Counsel of Minerva Neurosciences. The Form 3 specifically flags him as an officer of the company, while indicating he is not a director and not a ten percent owner.

Does the Minerva Neurosciences (NERV) Form 3 show any stock transactions?

The Form 3 shows no reportable transactions for James Joseph O'Connor. Transaction counts for buys, sells, exercises, gifts, tax withholding, and restructurings are all zero in the filing’s summarized transaction data.

Is James Joseph O'Connor a ten percent owner of Minerva Neurosciences (NERV)?

No, the Form 3 indicates James Joseph O'Connor is not a ten percent owner. The filing marks his status only as an officer of Minerva Neurosciences, with the ten percent owner box set to “0” in the provided data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 04:53 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Connor James Joseph

(Last) (First) (Middle)

C/O MINERVA NEUROSCIENCES, INC.

1500 DISTRICT AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/21/2026

3. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer and GC

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Fred Ahlholm, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)